Scarica l'app Stockscreener
1.11
4.72%
0.05
Pre-mercato:
1.12
0.01
+0.90%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché LXRX Giù?
Forum
Previsione
Frazionamento azionario
Lexicon Pharmaceuticals Inc Borsa (LXRX) Ultime notizie
What makes Lexicon Pharmaceuticals Inc. stock price move sharplyFree Technical Signal Summary - newsyoung.net
Is Lexicon Pharmaceuticals Inc. stock entering bullish territoryDay Trading Setup and Momentum Analysis - Newser
Has Lexicon Pharmaceuticals Inc. formed a bullish divergenceShort-Term Market Movement Forecast Report - Newser
Published on: 2025-08-11 05:26:29 - Newser
Real time alert setup for Lexicon Pharmaceuticals Inc. performanceAlpha Stock Picks with Chart Confirmation - Newser
Leerink Partnrs Brokers Increase Earnings Estimates for LXRX - Defense World
Will breakout in Lexicon Pharmaceuticals Inc. lead to full recoveryMarket Timing Strategy with Technical Filters - Newser
Top chart patterns to watch in Lexicon Pharmaceuticals Inc.Free Conservative Long Term Growth Plans - Newser
How high can Lexicon Pharmaceuticals Inc. stock price go in 20252-Day Signal Watch with Forecast Outcome - Newser
Trendline Breach Raises Concern for Lexicon Pharmaceuticals Inc. InvestorsWeekly Return Pick Forecast Reports Show Trend - metal.it
Lexicon Pharmaceuticals Inc. Stock Approaches Key Moving AverageTechnical Stock Breakout Predictions Signal Entry Points - beatles.ru
Lexicon Pharmaceuticals Advances Sotagliflozin Study for Hypertrophic Cardiomyopathy Treatment - AInvest
What momentum shifts mean for Lexicon Pharmaceuticals Inc.Predictive Model for Intraday Swing Forecast - Newser
How sentiment analysis helps forecast Lexicon Pharmaceuticals Inc.Community Picked Stocks with Trade Insights - Newser
Lexicon Pharmaceuticals Advances Study on Sotagliflozin for Hypertrophic Cardiomyopathy - TipRanks
Lexicon (LXRX) Upgraded to Buy: Here's What You Should Know - Yahoo Finance
Balanced Outlook for Lexicon Pharmaceuticals Amid Strategic Gains and Revenue Challenges - TipRanks
Citigroup Raises Lexicon Pharmaceuticals PT to $1.9, Maintains Buy Rating - AInvest
Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) Q2 2025 Earnings Call Transcript - Insider Monkey
Citi Maintains Lexicon Pharmaceuticals(LXRX.US) With Buy Rating, Raises Target Price to $1.9 - 富途牛牛
Lexicon: Q2 Earnings Snapshot - New Haven Register
Lexicon Pharmaceuticals 2025 Q2 Earnings Remarkable Turnaround with 106.1% Net Income Increase - AInvest
Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) Receives $3.67 Average Target Price from Analysts - Defense World
Lexicon Pharmaceuticals Reports Strong Q2 2025 Results - TipRanks
Jefferies raises Lexicon Pharmaceuticals stock price target to $0.85 By Investing.com - Investing.com Nigeria
Jefferies raises Lexicon Pharmaceuticals stock price target to $0.85 - Investing.com
Lexicon Pharmaceuticals’ Q2 2025: Navigating Contradictions in Trial Designs, Partnering Strategies, and Financial Guidance - AInvest
Lexicon Pharmaceuticals, Inc. 2025 Q2ResultsEarnings Call Presentation (NASDAQ:LXRX) - Seeking Alpha
Lexicon Pharmaceuticals Reports Surprising Q2 Earnings and RevenueNews and Statistics - IndexBox
Lexicon Pharmaceuticals (LXRX) Q2 Earnings and Revenues Top Estimates - sharewise.com
Lexicon Pharmaceuticals Q2 product revenue USD 1.322 million - MarketScreener
LEXICON PHARMACEUTICALS Earnings Results: $LXRX Reports Quarterly Earnings - Quiver Quantitative
Lexicon Pharmaceuticals Inc (LXRX) Reports Q2 2025 Earnings: EPS - GuruFocus
Lexicon Pharmaceuticals Reports Second Quarter 2025 Financial Results and Provides Business Updates - The Manila Times
Lexicon Pharmaceuticals Q2 EPS Surpasses Expectations, Revenue Jumps 1649.7% YoY - AInvest
Lexicon Pharmaceuticals reports Q2 results, Phase 2b PROGRESS study results, and Q3 enrollment target. - AInvest
Evaluating Lexicon Pharmaceuticals' Q2 2025 Earnings and Institutional Investor Sentiment: A Path to Value Creation Amid Mixed Analyst Ratings - AInvest
Published on: 2025-08-04 19:08:28 - metal.it
Lexicon Pharmaceuticals Inc expected to post a loss of 8 cents a shareEarnings Preview - TradingView
H.C. Wainwright Reiterates a Buy Rating on Lexicon Pharmaceuticals (LXRX) - MSN
Is Lexicon Pharmaceuticals Inc. stock overvalued or undervaluedBuild a winning investment strategy - Jammu Links News
Published on: 2025-08-04 02:57:12 - Jammu Links News
What is the risk reward ratio of investing in Lexicon Pharmaceuticals Inc. stockMarket-beating performance - Jammu Links News
What are Lexicon Pharmaceuticals Inc. company’s key revenue driversUnstoppable profit momentum - Jammu Links News
What are analysts’ price targets for Lexicon Pharmaceuticals Inc. in the next 12 monthsInvest smarter with real-time trading signals - Jammu Links News
What is the dividend policy of Lexicon Pharmaceuticals Inc. stockConsistent triple returns - Jammu Links News
Does Lexicon Pharmaceuticals Inc. stock perform well during market downturnsGet timely alerts on market movers - Jammu Links News
Should I hold or sell Lexicon Pharmaceuticals Inc. stock in 2025Tap into rapid wealth building techniques - Jammu Links News
Is Lexicon Pharmaceuticals Inc. a good long term investmentUnstoppable trading performance - Jammu Links News
How does Lexicon Pharmaceuticals Inc. generate profit in a changing economyMaximize portfolio value with smart investment plans - Jammu Links News
What drives Lexicon Pharmaceuticals Inc. stock priceSky-high profits - Jammu Links News
How volatile is Lexicon Pharmaceuticals Inc. stock compared to the marketCapitalize on momentum-driven stocks - Jammu Links News
Is Lexicon Pharmaceuticals Inc. a growth stock or a value stockBuild a portfolio with strong long-term growth - Jammu Links News
1.67%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):